GC
NAGE

Globeflex Capital’s Niagen Bioscience NAGE Stock Holding History

Globeflex Capital’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-37,594
Closed -$351K – 462
2025
Q3 		$351K Hold
37,594
– – 0.05% 270
2025
Q2 		$542K Hold
37,594
– – 0.04% 255
2025
Q1 		$259K Hold
37,594
– – 0.02% 299
2024
Q4 		$199K Hold
37,594
– – 0.02% 318
2024
Q3 		$137K Buy
+37,594
New +$118K 0.01% 351

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Globeflex Capital's NAGE Position: Q4 2025 in Review

Globeflex Capital sold out of Niagen Bioscience (NAGE) in Q4 2025, closing a stake of 37,594 shares — an estimated $351K sold.

Globeflex Capital first reported a position in NAGE in Q3 2024 and held it in 5 quarters. The position peaked at $542K in Q2 2025. 169 funds tracked by Wall St. Rank hold NAGE as of Q4 2025.

  • Globeflex Capital reported no remaining Niagen Bioscience position as of Q4 2025 after selling out during the quarter.
  • Globeflex Capital sold 37,594 Niagen Bioscience shares in Q4 2025, an estimated $351K.
  • Globeflex Capital first reported a position in Niagen Bioscience in Q3 2024 and held it in 5 quarters.
  • Globeflex Capital's Niagen Bioscience position peaked at $542K in Q2 2025.
  • 169 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2025.

Based on Globeflex Capital's 13F filing for Q4 2025, filed 11 Feb 2026.